• Still low number of patients entered the study in Q2-2022.
• A new Australian based CRO for SER150 CL-009 clinical study will continue the study on Serodus behalf.
• Complete transfer expected to be finalized mid Q3-2022.
• Australian ethical committee has approved increasing dosing period from 3 to 6 months.

Read more here